Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome
Clinical Nutrition · 2025
DOI: 10.1016/j.clnu.2025.05.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nutrition, 2025. Verfasst von Brune de Dreuille und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche sur l'Inflammation (CRI), INSERM U1149, Université Paris Cité, 75018 Paris, France; Gastroenterology and Nutritional Support Depa…. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Insulin-Like Growth Factor I, Peptides, Gastrointestinal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Société Francophone Nutrition Clinique et Métabolisme.
Abstract (Originalsprache)
BACKGROUND: Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is indicated to treat short bowel syndrome (SBS) since 2015. It has been shown to reduce parenteral support (PS) in SBS patients, although patients' response is quite heterogeneous. The exact mechanisms of action of GLP-2 on intestinal cells are still poorly understood. The aim of this study was to explore the intestinal action of teduglutide to identify molecular mechanisms underlying response heterogeneity. METHODS: A retrospective study was conducted in 39 SBS patients treated with teduglutide for at least 6 months. Intestinal biopsy specimens collected before and after treatment initiation were selected and analyzed by RNA sequencing to identify genes differentially expressed and pathways regulated following teduglutide treatment. RESULTS: Of the 39 patients included in the study, 29 (74%) had a colon in continuity. The overall response to teduglutide was a reduction by 75% (interquartile range: 42-100) in PS volume. Among the genes differentially expressed in the small bowel during teduglutide treatment, the most significantly upregulated gene was PAPPA2 (q-value < 0.0001), encoding the metalloproteinase Pappalysin-2 (PAPPA-2) involved in Insulin-like Growth Factor (IGF) bioavailability. The best responders to teduglutide showed a lower PAPPA2 expression at baseline (p < 0.01). PAPPA2 expression at baseline also correlated positively with the percentage of remnant colon (p < 0.001). CONCLUSION: We identified a new stakeholder, PAPPA-2, known to modulate IGF bioavailability, as playing a possible role in GLP-2 mechanism of action in human with SBS. We showed by association the existence of a greater spontaneous intestinal adaptation in SBS patients with a colon in continuity that could reduce sensitivity to teduglutide. Additionally, we suggest that initial PAPPA2 expression could serve as a predictive biomarker for teduglutide efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche sur l'Inflammation (CRI), INSERM U1149, Université Paris Cité, 75018 Paris, France; Gastroenterology and Nutritional Support Department, Hôpital Beaujon (AP-HP), Clichy, France.
- Centre de Recherche sur l'Inflammation (CRI), INSERM U1149, Université Paris Cité, 75018 Paris, France.
- Centre de Recherche sur l'Inflammation (CRI), INSERM U1149, Université Paris Cité, 75018 Paris, France; Pathology Department, Hôpital Beaujon (AP-HP), Clichy, France.
- Pathology Department, Hôpital Beaujon (AP-HP), Clichy, France.
- Pathology Department, Hôpital Bichat (AP-HP), Paris, France.
- Centre de Recherche sur l'Inflammation (CRI), INSERM U1149, Université Paris Cité, 75018 Paris, France; Endocrine and Oncological Biochemistry Department, Hôpital Pitié-Salpêtrière (AP-HP)-Sorbonne University, Paris, Fr…
Förderung
- Société Francophone Nutrition Clinique et Métabolisme
Zitieren
APA
de Dreuille, B., Nicolle, R., Cros, J., Cazals-Hatem, D., Chassac, A., Poté, N., Le Beyec-Le Bihan, J., Bado, A., Le Gall, M., & Joly, F. (2025). Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.05.006
Vancouver
de Dreuille B, Nicolle R, Cros J, Cazals-Hatem D, Chassac A, Poté N, et al. Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome. Clinical Nutrition. 2025. doi:10.1016/j.clnu.2025.05.006
BibTeX
@article{deDreuille2025,
author = {de Dreuille, Brune and Nicolle, Rémy and Cros, Jérôme and Cazals-Hatem, Dominique and Chassac, Anaïs and Poté, Nicolas and Le Beyec-Le Bihan, Johanne and Bado, André and Le Gall, Maude and Joly, Francisca},
title = {Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome},
journal = {Clinical Nutrition},
year = {2025},
doi = {10.1016/j.clnu.2025.05.006}
}
EUVIMED